Department of Immunology, Clinic of Specialized Medicine and Surgery Oslo University Hospital, Rikshospitalet, N-0027 Oslo, Norway.
N Biotechnol. 2012 Jun 15;29(5):578-85. doi: 10.1016/j.nbt.2011.07.008. Epub 2011 Aug 4.
Researchers who use protein binders in multiplexed assays can be divided into two camps. One believes that arrays with proteome-wide coverage will become a reality once we have developed binders for all proteins. The sceptics claim that detection with immobilized protein binders and sample labelling will not provide the required specificity. In this article, we review the evidence showing that antibody array analysis of labelled samples can provide meaningful data and discuss the issues raised by the sceptics. We argue that direct the evidence for monospecificity has yet to be published. This will require assays designed to resolve the proteins captured by each binder. One option is to combine array measurement with protein separation. We have developed an assay where labelled sample proteins are separated by size exclusion chromatography (SEC) before contact with microsphere-based arrays (Size-MAP; size exclusion chromatography-resolved microsphere-based affinity proteomics). The effect is an 'antibody array Western blot' where reactivity of immobilized binders is resolved against the size of the proteins in the sample. We show that Size-MAP is useful to discriminate monospecific- and polyreactive antibodies and for automatic detection of reacting with the same target. The possibility to test specificity directly in array-based measurement should be useful to select the best binders and to determine whether the DNA microarray for the proteome is a realistic goal or not.
在使用多重分析中蛋白质结合物的研究人员可以分为两派。一派认为,一旦我们为所有蛋白质开发出结合物,具有蛋白质组覆盖范围的阵列将成为现实。持怀疑态度的人则声称,固定化蛋白质结合物的检测和样品标记不会提供所需的特异性。在本文中,我们回顾了表明标记样品的抗体阵列分析可以提供有意义的数据的证据,并讨论了怀疑者提出的问题。我们认为,尚未发表针对单特异性的直接证据。这将需要设计旨在解析每个结合物捕获的蛋白质的测定法。一种选择是将阵列测量与蛋白质分离结合起来。我们开发了一种测定法,其中标记的样品蛋白质在与基于微球的阵列(Size-MAP;尺寸排阻色谱分离的基于微球的亲和蛋白质组学)接触之前通过大小排阻色谱(SEC)进行分离。其效果是一种“抗体阵列 Western blot”,其中固定化结合物的反应性与样品中蛋白质的大小相对应。我们表明,Size-MAP 可用于区分单特异性和多反应性抗体,并可用于自动检测与相同靶标反应的抗体。在基于阵列的测量中直接测试特异性的可能性应该有助于选择最佳的结合物,并确定用于蛋白质组的 DNA 微阵列是否是一个现实的目标。